Life-threatening mediastinal-retroperitoneal hemorrhage in a child with moderate hemophilia A and high inhibitor titer: Successful management with recombinant activated factor VII

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 7, 2005, Pages 400-402

  Yilmaz, Şebnem ^a   Ören, Hale ^a   Irken, Gülersu ^a   Atabay, Berna ^a   Duman, Murat ^a   Yilmaz, Ebru ^a   Çakmakçi, Handan ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Factor VIII inhibitor; Hemophilia A; Mediastinal and retroperitoneal bleeding; Recombinant activated factor VII

Indexed keywords

BLOOD CLOTTING FACTOR 7; PROCOAGULANT; RECOMBINANT ACTIVATED BLOOD CLOTTING FACTOR 7; UNCLASSIFIED DRUG;

ANTIBODY TITER; BLEEDING; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONSERVATIVE TREATMENT; DISEASE SEVERITY; FEMALE; HEMOPHILIA A; HEMOSTASIS; HUMAN; MEDIASTINUM; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; THORAX RADIOGRAPHY;

ADULT; FACTOR VII; HEMATOMA; HEMOPERITONEUM; HEMOPHILIA A; HUMANS; MALE; RADIOGRAPHY, THORACIC; RECOMBINANT PROTEINS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 23044507032     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000174241.03038.b5     Document Type: Conference Paper

References (24)

1. Ehrenfort S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and IX inhibitor in haemophilia. Lancet. 1992;339:594-598.
2. Oren H, Yaprak I, Irken G. Factor VIII inhibitors in patients with hemophilia A. Acta Haematol. 1999;102:42-46.
3. Brettler DB. Inhibitors in congenital haemophilia. Baillieres Clin Haematol. 1996;9:319-329.
4. Schwaab R, Brackmann H, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995;74:1402-1406.
5. Oldenburg J, Schroder J, Graw J, et al. Significance of mutation analysis in patients with haemophilia A. Hamostaseologie. 2003;23:6-12.
6. Citron M, Godmilow L, Ganguly T, et al. High throughput mutation screening of the factor VIII gene (F8C) in hemophilia A: 37 novel mutations and genotype-phenotype correlation. Hum Mutat. 2002;20:267-274.
7. Polakova H, Kadasi L, Filova A. Analysis of inversion in intron 22 of the factor F VIII:C gene in patients with hemophilia A in the Slovak population. Bratisl Lek Listy. 1998;99:538-542.
8. Yenchitsomanus P, Akkarapatumwong V, Pung-Amritt P, et al. Genotype and phenotype of haemophilia A in Thai patients. Haemophilia. 2003;9: 179-186.
9. Oldenburg J, Picard JK, Schwaab R, et al. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost. 1997;77:238-242.
10. Peerlinck K, Arnout J, Gilles JG, et al. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate-purity pasteurized factor VIII concentrate. Thromb Haemost. 1993;69:115-118.
11. Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost. 1998;79:762-766.
12. Pendergrass E, Neuhauser E. Pleural lesions in hemophilia. AJR Am J Roentgenol. 1942;48:147-151.
13. Freedman P, Levine S, Solis-Cohen L. Hemothorax in blood dyscrasias. Am J Med Sci. 1943;205:692-696.
14. Kay W, Kupfer H. Spontaneous hemothorax in hemophilia: case report and discussion of the hemophiliac syndromes, with remarks on the management of hemothorax. Ann Intern Med. 1957;47:152-161.
15. Burke J, Solzman E. Spontaneous hemopneumothorax in a hemophiliac. JAMA. 1959;169:1623-1625.
16. Barrett K, Israels M. Hemothorax in hemophilia. Thorax. 1965;20:416-421.
17. Bart JB. Hemomediastinum and hemothorax in mild hemophilia. South Med J. 1972;65:159-160.
18. Rasaretnam R, Chanmugam D, Sivathasan C. Spontaneous haemothorax in a mild haemophiliac. Thorax. 1976;31:601-604.
19. Wilimas JA, Presbury G, Orenstein D, et al. Hemothorax and hemomediastinum in patients with hemophilia. Acta Haematol. 1985;73:176-178.
20. Meili EO, Dazzi H, von Felten A. Recombinant activated factor VII (Novoseven™ Novo Nordisk) for hemostasis in a patient with an acquired factor VIII inhibitor. Schweiz Med Wochenschr. 1995;125: 405-411.
21. Ng SC. Activated recombinant factor VII in the treatment of retroperitoneal haemorrhage in a patient with factor VIII inhibitor. Ann Acad Med Singapore. 1994;23:901-902.
22. Liebman HA, Chediak J, Fink KJ, et al. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol. 2000;63:109-113.
23. Johannessen M, Andreasen RB, Nordfang O. Decline of factor VIII and factor IX inhibitors during long-term treatment with Novoseven®. Blood Coagul Fibrinolysis. 2000;11:239-242.
24. Nicolaisen EM, Hansen LL, Poulsen F, et al. Immunological aspects of recombinant factor VII (rFVIIa) in clinical use. Thromb Haemost. 1996; 76:200-204.